Emcure Pharmaceuticals Ltd
Trastuzumab (440mg)
Trazumab 440mg Solution for Infusion is used in the treatment of breast and stomach cancer, working by killing cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein).
Solution for Infusion
Trazumab 440mg Solution for Infusion is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Your doctor or nurse will give you this medicine. Kindly do not self-administer.
Nausea Headache Rash Insomnia Infection
Trazumab 440mg Solution for Infusion may cause excessive drowsiness with alcohol.
Trazumab 440mg Solution for Infusion is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Trazumab 440mg Solution for Infusion is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Trazumab 440mg Solution for Infusion is a recombinant IgG1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the over-proliferation of cancer cells in breast cancer and stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways.
It is given as an injection into your vein or under the skin usually over 1 hour. Use effective contraception method to prevent pregnancy while taking this medicine and for 7 months after you stop the treatment. Your doctor will monitor your heart regularly while taking this medicine. Inform your doctor if you notice symptoms such as breathlessness, cough, shivering, swelling of legs and arm. Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.
Serious side effects of Trazumab 440mg Solution for Infusion can include sore throat, fever, chills, excessive tiredness, pale skin, nosebleeds, and other unusual bruising or bleeding. Additionally, you may experience stomach pain, seizures, hallucinations, muscle cramps, spasms, nausea or vomiting, loss of appetite, fatigue, rapid heartbeat, discoloration of urine, decreased amount of urine, difficulty urinating, pain when urinating, and signs of infection. If you notice any of these symptoms, contact your doctor immediately.
Women of child-bearing age should use effective contraception during Trazumab 440mg Solution for Infusion therapy and for at least 7 months after completing treatment. You can plan your pregnancy after this 7-month waiting period.
Patients with early breast cancer should take Trazumab 440mg Solution for Infusion for 1 year or until disease recurrence, whichever occurs first. It is not recommended to extend treatment beyond 1 year in these patients.
No, fasting is not necessary before receiving Trazumab 440mg Solution for Infusion. This medication should be given under the guidance of an experienced healthcare professional and administered only by a qualified healthcare provider.
There are two formulations available: one is given as an intravenous infusion into a vein, while the other is administered as a subcutaneous injection under the skin. Ensure that you receive the correct formulation as prescribed by your doctor.
No, Trazumab 440mg Solution for Infusion is not effective in HER2-negative patients, as it targets the HER2 protein. It should only be used in patients with HER2-positive cancer cells.
When used with anthracycline-class anti-cancer medicines (such as doxorubicin), Trazumab 440mg Solution for Infusion may affect the heart. Therefore, your doctor needs to check the health of your heart initially and regularly throughout treatment.
Heart investigations should be conducted at the start of treatment, every 3 months during treatment, and every 6 months after discontinuing treatment until 24 months from the last administration. Patients with pre-existing heart problems may require more frequent testing.